Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
losartan potassium and hydrochlorothiazide
Overview
What is losartan potassium and hydrochlorothiazide?
Losartan potassium and hydrochlorothiazide tablets 50/12.5 mg, losartan potassium and hydrochlorothiazide tablets 100/12.5 mg and losartan potassium and hydrochlorothiazide tablets 100/25 mg combine an angiotensin II receptor (type AT) antagonist and a diuretic, hydrochlorothiazide.
Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[(-1-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt. Its empirical formula is CHClKNO, and its structural formula is:
Losartan potassium is a white to off-white free-flowing crystalline powder with a molecular weight of 461.01. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone.
Oxidation of the 5-hydroxymethyl group on the imidazole ring results in the active metabolite of losartan.
Hydrochlorothiazide is 6-chloro-3,4-dihydro-2-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is CHClNOS and its structural formula is:
Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.74, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.
Losartan potassium and hydrochlorothiazide tablets are available for oral administration in three tablet combinations of losartan and hydrochlorothiazide. Losartan potassium and hydrochlorothiazide tablets 50/12.5 mg contain 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide. Losartan potassium and hydrochlorothiazide tablets 100/12.5 mg contain 100 mg of losartan potassium and 12.5 mg of hydrochlorothiazide. Losartan potassium and hydrochlorothiazide tablets 100/25 mg contain 100 mg of losartan potassium and 25 mg of hydrochlorothiazide. Inactive ingredients are microcrystalline cellulose, lactose hydrous, pregelatinized starch, magnesium stearate, hydroxypropyl cellulose, hypromellose, and titanium dioxide. Losartan potassium and hydrochlorothiazide tablets 50/12.5 mg and losartan potassium and hydrochlorothiazide tablets 100/25 mg also contain D&C yellow No. 10 aluminum lake. Losartan potassium and hydrochlorothiazide tablets 50/12.5 mg, losartan potassium and hydrochlorothiazide tablets 100/12.5 mg, and losartan potassium and hydrochlorothiazide tablets 100/25 mg may also contain carnauba wax.
Losartan potassium and hydrochlorothiazide tablets 50/12.5 mg contain 4.24 mg (0.108 mEq) of potassium, losartan potassium and hydrochlorothiazide tablets 100/12.5 mg contain 8.48 mg (0.216 mEq) of potassium, and losartan potassium and hydrochlorothiazide tablets 100/25 mg contain 8.48 mg (0.216 mEq) of potassium.
What does losartan potassium and hydrochlorothiazide look like?
What are the available doses of losartan potassium and hydrochlorothiazide?
Sorry No records found.
What should I talk to my health care provider before I take losartan potassium and hydrochlorothiazide?
Sorry No records found
How should I use losartan potassium and hydrochlorothiazide?
Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see and ).
Dosing must be individualized. The usual starting dose of losartan is 50 mg once daily, with 25 mg recommended for patients with intravascular volume depletion (e.g., patients treated with diuretics) (see ) and patients with a history of hepatic impairment (see ). Losartan can be administered once or twice daily at total daily doses of 25 to 100 mg. If the antihypertensive effect measured at trough using once-a-day dosing is inadequate, a twice-a-day regimen at the same total daily dose or an increase in dose may give a more satisfactory response.
Hydrochlorothiazide is effective in doses of 12.5 to 50 mg once daily and can be given at doses of 12.5 to 25 mg as losartan potassium and hydrochlorothiazide tablets.
To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy.
The side effects (see ) of losartan are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent (primarily hypokalemia) and dose-independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with any combination of losartan and hydrochlorothiazide will be associated with both sets of dose-independent side effects.
Replacement Therapy:
Dose Titration by Clinical Effect:
A patient whose blood pressure is inadequately controlled by 25 mg once daily of hydrochlorothiazide, or is controlled but who experiences hypokalemia with this regimen, may be switched to losartan potassium and hydrochlorothiazide tablets 50/12.5 mg (losartan 50 mg/hydrochlorothiazide 12.5 mg) once daily, reducing the dose of hydrochlorothiazide without reducing the overall expected antihypertensive response. The clinical response to losartan potassium and hydrochlorothiazide tablets 50/12.5 mg should be subsequently evaluated, and if blood pressure remains uncontrolled after about 3 weeks of therapy, the dose may be increased to two tablets of losartan potassium and hydrochlorothiazide tablets 50/12.5 mg once daily or one tablet of losartan potassium and hydrochlorothiazide tablets 100/25 mg (losartan 100 mg/hydrochlorothiazide 25 mg) once daily.
The usual dose of losartan potassium and hydrochlorothiazide tablets is one tablet of losartan potassium and hydrochlorothiazide tablets 50/12.5 mg once daily. More than two tablets of losartan potassium and hydrochlorothiazide tablets 50/12.5 mg once daily or more than one tablet of losartan potassium and hydrochlorothiazide tablets 100/25 mg once daily is not recommended. The maximal antihypertensive effect is attained about 3 weeks after initiation of therapy.
Use in Patients with Renal Impairment:
Patients with Hepatic Impairment:
What interacts with losartan potassium and hydrochlorothiazide?
Sorry No Records found
What are the warnings of losartan potassium and hydrochlorothiazide?
Fetal/Neonatal Morbidity and Mortality
Drugs that act directly on the renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature in patients who were taking angiotensin converting enzyme inhibitors. When pregnancy is detected, losartan potassium and hydrochlorothiazide tablets should be discontinued as soon as possible.
The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death. Oligohydramnios has also been reported, presumably resulting from decreased fetal renal function; oligohydramnios in this setting has been associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Prematurity, intrauterine growth retardation, and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug.
These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester.
Mothers whose embryos and fetuses are exposed to an angiotensin II receptor antagonist only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of losartan potassium and hydrochlorothiazide tablets as soon as possible.
Rarely (probably less often than once in every thousand pregnancies), no alternative to an angiotensin II receptor antagonist will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intra-amniotic environment.
If oligohydramnios is observed, losartan potassium and hydrochlorothiazide tablets should be discontinued unless they are considered life-saving for the mother. Contraction stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.
Infants with histories of exposure to an angiotensin II receptor antagonist should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function.
There was no evidence of teratogenicity in rats or rabbits treated with a maximum losartan potassium dose of 10 mg/kg/day in combination with 2.5 mg/kg/day of hydrochlorothiazide. At these dosages, respective exposures (AUCs) of losartan, its active metabolite, and hydrochlorothiazide in rabbits were approximately 5, 1.5, and 1.0 times those achieved in humans with 100 mg losartan in combination with 25 mg hydrochlorothiazide. AUC values for losartan, its active metabolite and hydrochlorothiazide, extrapolated from data obtained with losartan administered to rats at a dose of 50 mg/kg/day in combination with 12.5 mg/kg/day of hydrochlorothiazide, were approximately 6, 2, and 2 times greater than those achieved in humans with 100 mg of losartan in combination with 25 mg of hydrochlorothiazide. Fetal toxicity in rats, as evidenced by a slight increase in supernumerary ribs, was observed when females were treated prior to and throughout gestation with 10 mg/kg/day losartan in combination with 2.5 mg/kg/day hydrochlorothiazide. As also observed in studies with losartan alone, adverse fetal and neonatal effects, including decreased body weight, renal toxicity, and mortality, occurred when pregnant rats were treated during late gestation and/or lactation with 50 mg/kg/day losartan in combination with 12.5 mg/kg/day hydrochlorothiazide. Respective AUCs for losartan, its active metabolite, and hydrochlorothiazide at these dosages in rats were approximately 35, 10, and 10 times greater than those achieved in humans with the administration of 100 mg of losartan in combination with 25 mg hydrochlorothiazide. When hydrochlorothiazide was administered without losartan to pregnant mice and rats during their respective periods of major organogenesis, at doses up to 3000 and 1000 mg/kg/day, respectively, there was no evidence of harm to the fetus.
Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse reactions that have occurred in adults.
Hypotension — Volume-Depleted Patients
In patients who are intravascularly volume-depleted (e.g., those treated with diuretics), symptomatic hypotension may occur after initiation of therapy with losartan potassium and hydrochlorothiazide tablets. This condition should be corrected prior to administration of losartan potassium and hydrochlorothiazide tablets (see ).
Impaired Hepatic Function
Losartan potassium and hydrochlorothiazide tablets are not recommended for patients with hepatic impairment who require titration with losartan. The lower starting dose of losartan recommended for use in patients with hepatic impairment cannot be given using losartan potassium and hydrochlorothiazide tablets.
Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Hypersensitivity Reaction
Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.
Systemic Lupus Erythematosus
Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.
Lithium Interaction
Lithium generally should not be given with thiazides (see ).
What are the precautions of losartan potassium and hydrochlorothiazide?
General
Hypersensitivity:
In double-blind clinical trials of various doses of losartan potassium and hydrochlorothiazide, the incidence of hypertensive patients who developed hypokalemia (serum potassium <3.5 mEq/L) was 6.7% versus 3.5% for placebo; the incidence of hyperkalemia (serum potassium >5.7 mEq/L) was 0.4%. No patient discontinued due to increases or decreases in serum potassium. The mean decrease in serum potassium in patients treated with various doses of losartan and hydrochlorothiazide was 0.123 mEq/L. In patients treated with various doses of losartan and hydrochlorothiazide, there was also a dose-related decrease in the hypokalemic response to hydrochlorothiazide as the dose of losartan was increased, as well as a dose-related decrease in serum uric acid with increasing doses of losartan.
Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals.
All patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance: hyponatremia, hypochloremic alkalosis, and hypokalemia. Serum and urine electrolyte determinations are particularly important when the patient is vomiting excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance, irrespective of cause, include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.
Hypokalemia may develop, especially with brisk diuresis, when severe cirrhosis is present, or after prolonged therapy.
Interference with adequate oral electrolyte intake will also contribute to hypokalemia. Hypokalemia may cause cardiac arrhythmia and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular irritability).
Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or renal disease), chloride replacement may be required in the treatment of metabolic alkalosis.
Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the hyponatremia is life-threatening. In actual salt depletion, appropriate replacement is the therapy of choice.
Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy. Because losartan decreases uric acid, losartan in combination with hydrochlorothiazide attenuates the diuretic-induced hyperuricemia.
In diabetic patients, dosage adjustments of insulin or oral hypoglycemic agents may be required. Hyperglycemia may occur with thiazide diuretics. Thus latent diabetes mellitus may become manifest during thiazide therapy.
The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.
If progressive renal impairment becomes evident, consider withholding or discontinuing diuretic therapy.
Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia.
Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.
Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy.
Impaired Renal Function
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function have been reported in susceptible individuals treated with losartan; in some patients, these changes in renal function were reversible upon discontinuation of therapy.
In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar outcomes have been reported with losartan.
In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or BUN have been reported. Similar effects have been reported with losartan; in some patients, these effects were reversible upon discontinuation of therapy.
Thiazides should be used with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.
Information for Patients
Pregnancy:
Symptomatic Hypotension:
All patients should be cautioned that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.
Potassium Supplements:
Drug Interactions
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, cimetidine, and phenobarbital. Rifampin, an inducer of drug metabolism, decreased the concentrations of losartan and its active metabolite. (See .) In humans, two inhibitors of P450 3A4 have been studied. Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration. Fluconazole, an inhibitor of P450 2C9, decreased active metabolite concentration and increased losartan concentration. The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined. Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9. These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.
As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium (see ).
Lithium:
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors):
The antihypertensive effect of angiotensin II receptor antagonists, including losartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.
When administered concurrently, the following drugs may interact with thiazide diuretics:
Alcohol, barbiturates, or narcotics
Antidiabetic drugs (oral agents and insulin)
Other antihypertensive drugs
Cholestyramine and colestipol resins
Corticosteroids, ACTH
Pressor amines (e.g., norepinephrine)
Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)
Lithium
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
In patients receiving diuretic therapy, co-administration of NSAIDs with angiotensin receptor blockers, including losartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving hydrochlorothiazide, losartan, and NSAID therapy.
Carcinogenesis, Mutagenesis, Impairment of Fertility
No carcinogenicity studies have been conducted with the losartan potassium and hydrochlorothiazide combination.
Losartan potassium and hydrochlorothiazide tablets when tested at a weight ratio of 4:1 were negative in the Ames microbial mutagenesis assay and the V-79 Chinese hamster lung cell mutagenesis assay. In addition, there was no evidence of direct genotoxicity in thealkaline elution assay in rat hepatocytes and chromosomal aberration assay in Chinese hamster ovary cells at noncytotoxic concentrations.
Losartan potassium, coadministered with hydrochlorothiazide, had no effect on the fertility or mating behavior of male rats at dosages up to 135 mg/kg/day of losartan and 33.75 mg/kg/day of hydrochlorothiazide. These dosages have been shown to provide respective systemic exposures (AUCs) for losartan, its active metabolite and hydrochlorothiazide that are approximately 60, 60, and 30 times greater than those achieved in humans with 100 mg of losartan potassium in combination with 25 mg of hydrochlorothiazide. In female rats, however, the coadministration of doses as low as 10 mg/kg/day of losartan and 2.5 mg/kg/day of hydrochlorothiazide was associated with slight but statistically significant decreases in fecundity and fertility indices. AUC values for losartan, its active metabolite and hydrochlorothiazide, extrapolated from data obtained with losartan administered to rats at a dose of 50 mg/kg/day in combination with 12.5 mg/kg/day of hydrochlorothiazide, were approximately 6, 2, and 2 times greater than those achieved in humans with 100 mg of losartan in combination with 25 mg of hydrochlorothiazide.
Losartan potassium was not carcinogenic when administered at maximally tolerated dosages to rats and mice for 105 and 92 weeks, respectively. Female rats given the highest dose (270 mg/kg/day) had a slightly higher incidence of pancreatic acinar adenoma. The maximally tolerated dosages (270 mg/kg/day in rats, 200 mg/kg/day in mice) provided systemic exposures for losartan and its pharmacologically active metabolite that were approximately 160 and 90 times (rats) and 30 and 15 times (mice) the exposure of a 50 -kg human given 100 mg per day.
Losartan potassium was negative in the microbial mutagenesis and V-79 mammalian cell mutagenesis assays and in the alkaline elution and and chromosomal aberration assays. In addition, the active metabolite showed no evidence of genotoxicity in the microbial mutagenesis, alkaline elution, and chromosomal aberration assays.
Fertility and reproductive performance were not affected in studies with male rats given oral doses of losartan potassium up to approximately 150 mg/kg/day. The administration of toxic dosage levels in females (300/200 mg/kg/day) was associated with a significant (p<0.05) decrease in the number of corpora lutea/female, implants/female, and live fetuses/female at C-section. At 100 mg/kg/day only a decrease in the number of corpora lutea/female was observed. The relationship of these findings to drug-treatment is uncertain since there was no effect at these dosage levels on implants/pregnant female, percent post-implantation loss, or live animals/litter at parturition. In nonpregnant rats dosed at 135 mg/kg/day for 7 days, systemic exposure (AUCs) for losartan and its active metabolite were approximately 66 and 26 times the exposure achieved in man at the maximum recommended human daily dosage (100 mg).
Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.
Hydrochlorothiazide was not genotoxic in the Ames mutagenicity assay of strains TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the sex-linked recessive lethal trait gene. Positive test results were obtained only in the CHO Sister Chromatid Exchange (clastogenicity) and in the Mouse Lymphoma Cell (mutagenicity) assays, using concentrations of hydrochlorothiazide from 43 to 1300 μg/mL, and in the non-disjunction assay at an unspecified concentration.
Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to mating and throughout gestation.
Pregnancy
Pregnancy Categories C (first trimester) and D (second and third trimesters). See .
Nursing Mothers
It is not known whether losartan is excreted in human milk, but significant levels of losartan and its active metabolite were shown to be present in rat milk. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness of losartan potassium and hydrochlorothiazide tablets in pediatric patients have not been established.
Geriatric Use
In a controlled clinical study for the reduction in the combined risk of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy, 2857 patients (62%) were 65 years and over, while 808 patients (18%) were 75 years and over. In an effort to control blood pressure in this study, patients were coadministered losartan and hydrochlorothiazide 74% of the total time they were on study drug. No overall differences in effectiveness were observed between these patients and younger patients. Adverse events were somewhat more frequent in the elderly compared to non-elderly patients for both the losartan-hydrochlorothiazide and the control groups (see ).
Race
In the LIFE study, Black patients with hypertension and left ventricular hypertrophy had a lower risk of stroke on atenolol than on losartan (both cotreated with hydrochlorothiazide in the majority of patients). Given the difficulty in interpreting subset differences in large trials, it cannot be known whether the observed difference is the result of chance. However, the LIFE study does not provide evidence that the benefits of losartan on reducing the risk of cardiovascular events in hypertensive patients with left ventricular hypertrophy apply to Black patients. (See .)
What are the side effects of losartan potassium and hydrochlorothiazide?
Losartan potassium and hydrochlorothiazide tablets have been evaluated for safety in 858 patients treated for essential hypertension and 3889 patients treated for hypertension and left ventricular hypertrophy. In clinical trials with losartan potassium and hydrochlorothiazide tablets, no adverse experiences peculiar to this combination have been observed. Adverse experiences have been limited to those that were reported previously with losartan potassium and/or hydrochlorothiazide. The overall incidence of adverse experiences reported with the combination was comparable to placebo.
In general, treatment with losartan potassium and hydrochlorothiazide tablets was well tolerated. For the most part, adverse experiences have been mild and transient in nature and have not required discontinuation of therapy. In controlled clinical trials, discontinuation of therapy due to clinical adverse experiences was required in only 2.8% and 2.3% of patients treated with the combination and placebo, respectively.
In these double-blind controlled clinical trials, the following adverse experiences reported with losartan potassium and hydrochlorothiazide tablets occurred in ≥1 percent of patients, and more often on drug than placebo, regardless of drug relationship:
The following adverse events were also reported at a rate of 1% or greater, but were as, or more, common in the placebo group in studies of essential hypertension: asthenia/fatigue, diarrhea, nausea, headache, bronchitis, pharyngitis.
Adverse events occurred at about the same rates in men and women. Adverse events were somewhat more frequent in the elderly compared to non-elderly patients and somewhat more frequent in Blacks compared to non-Blacks for both the losartan-hydrochlorothiazide and the control groups.
A patient with known hypersensitivity to aspirin and penicillin, when treated with losartan potassium, was withdrawn from study due to swelling of the lips and eyelids and facial rash, reported as angioedema, which returned to normal 5 days after therapy was discontinued.
Superficial peeling of palms and hemolysis were reported in one subject treated with losartan potassium.
| Losartan Potassium andHydrochlorothiazide Tablets(n=858) | ||
| Body as a Whole | ||
| Cardiovascular | ||
| Musculoskeletal | ||
| Nervous/Psychiatric | ||
| Respiratory | ||
| Skin |
Losartan Potassium
Other adverse experiences that have been reported with losartan, without regard to causality, are listed below:
Body as a Whole:
Cardiovascular:
Digestive:
General disorders and administration site conditions:
Hematologic:
Metabolic:
Musculoskeletal:
Nervous System/Psychiatric:
Respiratory:
Skin:
Special Senses:
Urogenital:
Hydrochlorothiazide
Other adverse experiences that have been reported with hydrochlorothiazide, without regard to causality, are listed below:
Body as a Whole:
Digestive:
Hematologic:
Hypersensitivity:
Metabolic:
Musculoskeletal:
Nervous System/Psychiatric:
Renal:
Skin:
Special Senses:
Persistent dry cough (with an incidence of a few percent) has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy. Two prospective, parallel-group, double-blind, randomized, controlled trials were conducted to assess the effects of losartan on the incidence of cough in hypertensive patients who had experienced cough while receiving ACE-inhibitor therapy. Patients who had typical ACE-inhibitor cough when challenged with lisinopril, whose cough disappeared on placebo, were randomized to losartan 50 mg, lisinopril 20 mg, or either placebo (one study, n=97) or 25 mg hydrochlorothiazide (n=135). The double-blind treatment period lasted up to 8 weeks. The incidence of cough is shown below.
These studies demonstrate that the incidence of cough associated with losartan therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with hydrochlorothiazide or placebo therapy.
Cases of cough, including positive re-challenges, have been reported with the use of losartan in post-marketing experience.
| Study 1 | HCTZ | Losartan | Lisinopril |
| Cough | 25% | 17% | 69% |
| Study 2 | Placebo | Losartan | Lisinopril |
| Cough | 35% | 29% | 62% |
Severe Hypertension
In a clinical study in patients with severe hypertension (SiDBP ≥110 mmHg), the overall pattern of adverse events reported through six weeks of follow-up was similar in patients treated with losartan potassium and hydrochlorothiazide tablets as initial therapy and in patients treated with losartan as initial therapy. There were no reported cases of syncope in either treatment group. There were 2 (0.6%) and 0 (0.0%) cases of hypotension reported in the group treated with losartan potassium and hydrochlorothiazide tablets and the group treated with losartan, respectively. There were 3 (0.8%) and 2 (1.2%) cases of increased serum creatinine (>0.5 mg/dL) in the group treated with losartan potassium and hydrochlorothiazide tablets and the group treated with losartan, respectively, during the same time period. (See .)
Post-Marketing Experience
The following additional adverse reactions have been reported in post-marketing experience:
Digestive:
Hemic:
Hypersensitivity:
Metabolic and Nutrition:
Musculoskeletal:
Respiratory:
Skin:
Laboratory Test Findings
In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of losartan potassium and hydrochlorothiazide tablets.
Creatinine, Blood Urea Nitrogen:
Hemoglobin and Hematocrit:
Liver Function Tests:
Serum Electrolytes:
What should I look out for while using losartan potassium and hydrochlorothiazide?
Losartan potassium and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product.
Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
What might happen if I take too much losartan potassium and hydrochlorothiazide?
How should I store and handle losartan potassium and hydrochlorothiazide?
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.No. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo. 6517—Losartan Potassium and Hydrochlorothiazide Tablets 50/12.5 mg are yellow, oval, film-coated tablets coded 717 on one side and plain on the other. Each tablet contains 50 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDCNo.6729—Losartan Potassium and Hydrochlorothiazide Tablets 100/12.5 mg are white, oval, film-coated tablets coded 745 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 12.5 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC No.6596—Losartan Potassium and Hydrochlorothiazide Tablets 100/25 mg are light yellow, oval, film-coated tablets coded 747 on one side and plain on the other. Each tablet contains 100 mg losartan potassium and 25 mg of hydrochlorothiazide. They are supplied as follows:NDCNDCNDC
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)], is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). There is also an AT receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Both losartan and its principal active metabolite do not exhibit any partial agonist activity at the AT receptor and have much greater affinity (about 1000-fold) for the AT receptor than for the AT receptor. binding studies indicate that losartan is a reversible, competitive inhibitor of the AT receptor. The active metabolite is 10 to 40 times more potent by weight than losartan and appears to be a reversible, non-competitive inhibitor of the AT receptor.
Neither losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin); nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.
The mechanism of the antihypertensive effect of thiazides is unknown.
Non-Clinical Toxicology
Losartan potassium and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product.Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.
Hypersensitivity:
ADVERSE REACTIONS, Post-Marketing Experience
Losartan potassium and hydrochlorothiazide tablets have been evaluated for safety in 858 patients treated for essential hypertension and 3889 patients treated for hypertension and left ventricular hypertrophy. In clinical trials with losartan potassium and hydrochlorothiazide tablets, no adverse experiences peculiar to this combination have been observed. Adverse experiences have been limited to those that were reported previously with losartan potassium and/or hydrochlorothiazide. The overall incidence of adverse experiences reported with the combination was comparable to placebo.
In general, treatment with losartan potassium and hydrochlorothiazide tablets was well tolerated. For the most part, adverse experiences have been mild and transient in nature and have not required discontinuation of therapy. In controlled clinical trials, discontinuation of therapy due to clinical adverse experiences was required in only 2.8% and 2.3% of patients treated with the combination and placebo, respectively.
In these double-blind controlled clinical trials, the following adverse experiences reported with losartan potassium and hydrochlorothiazide tablets occurred in ≥1 percent of patients, and more often on drug than placebo, regardless of drug relationship:
The following adverse events were also reported at a rate of 1% or greater, but were as, or more, common in the placebo group in studies of essential hypertension: asthenia/fatigue, diarrhea, nausea, headache, bronchitis, pharyngitis.
Adverse events occurred at about the same rates in men and women. Adverse events were somewhat more frequent in the elderly compared to non-elderly patients and somewhat more frequent in Blacks compared to non-Blacks for both the losartan-hydrochlorothiazide and the control groups.
A patient with known hypersensitivity to aspirin and penicillin, when treated with losartan potassium, was withdrawn from study due to swelling of the lips and eyelids and facial rash, reported as angioedema, which returned to normal 5 days after therapy was discontinued.
Superficial peeling of palms and hemolysis were reported in one subject treated with losartan potassium.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).